Divisions of Molecular Medicine and Genetics and Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, and Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Cancer Res. 2013 Sep 1;73(17):5591-602. doi: 10.1158/0008-5472.CAN-13-1351. Epub 2013 Jul 5.
Mammary stem cells (MaSC) and progenitor cells are important for mammary gland development and maintenance and may give rise to mammary cancer stem cells (MaCSC). Yet, there remains limited understanding of how these cells contribute to tumorigenesis. Here, we show that conditional deletion of focal adhesion kinase (FAK) in embryonic mammary epithelial cells (MaEC) decreases luminal progenitors and basal MaSCs, reducing their colony-forming and regenerative potentials in a cell-autonomous manner. Loss of FAK kinase activity in MaECs specifically impaired luminal progenitor proliferation and alveologenesis, whereas a kinase-independent activity of FAK supported ductal invasion and basal MaSC activity. Deficiency in luminal progenitors suppressed tumorigenesis and MaCSC formation in a mouse model of breast cancer. In contrast with the general inhibitory effect of FAK attenuation, inhibitors of FAK kinase preferentially inhibited proliferation and tumorsphere formation of luminal progenitor-like, but not MaSC-like, human breast cancer cells. Our findings establish distinct kinase-dependent and -independent activities of FAK that differentially regulate luminal progenitors and basal MaSCs. We suggest that targeting these distinct functions may tailor therapeutic strategies to address breast cancer heterogeneity more effectively.
乳腺干细胞(MaSC)和祖细胞对于乳腺发育和维持很重要,并且可能产生乳腺癌症干细胞(MaCSC)。然而,对于这些细胞如何促进肿瘤发生仍然存在有限的认识。在这里,我们表明,在胚胎乳腺上皮细胞(MaEC)中条件性缺失粘着斑激酶(FAK)会减少腔前体细胞和基底 MaSC,以细胞自主的方式降低它们的集落形成和再生潜力。FAK 激酶活性的丧失特异性地损害了腔前体细胞的增殖和肺泡发生,而 FAK 的激酶非依赖性活性则支持导管侵袭和基底 MaSC 活性。腔前体细胞的缺失抑制了乳腺癌小鼠模型中的肿瘤发生和 MaCSC 形成。与 FAK 衰减的一般抑制作用相反,FAK 激酶抑制剂优先抑制腔前体细胞样但不是 MaSC 样人乳腺癌细胞的增殖和肿瘤球形成。我们的研究结果确立了 FAK 的不同激酶依赖性和非依赖性活性,这些活性可差异调节腔前体细胞和基底 MaSC。我们认为,针对这些不同的功能可能会更有效地制定针对乳腺癌异质性的治疗策略。